Adaptive ADPT 深 沪
等待开盘 06-26 09:30:00 美东时间
20.245
+0.905
+4.68%
华盛通- 最 高20.64
- 今 开19.57
- 成交量 354.86万股
- 最 低 17.1327
- 昨 收 19.34
- 总市值 287.48万
- 52周最高 20.76
- 市盈率 静 --
- 换手率 2498.98%
- 52周最低 9.9551
- 委 比 40.03%
- 总股本 0.00亿
- 历史最高 71.25
- 量 比 0.46
- 振 幅 18.13%
- 历史最低 1.10
- 每 手 1
- 风险率 2.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adaptive Biotechnologies Business Separation May Unlock Greater Value
William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve flexibility and support valuation.
06-18 01:21
Adaptive Biotechnologies Prices $300M Upsized Convertible Notes Offering (Up From $250M)
Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 (the "notes")
06-17 18:03
VinFast Unveils VF 8 All-Electric SUV From $39,900
As electric vehicles continue to reshape the automotive landscape, family expectations around mobility are evolving as well. Today's drivers are looking for more than just transportation. They want comfort, safety,
06-01 18:40
Adaptive Biotechnologies shares are trading lower. The company reported Q4 financial results.
Adaptive Biotechnologies shares are trading lower. The company reported Q4 fina...
02-07 02:50
Adaptive Biotechnologies Q4 Earnings Assessment
The Q4 earnings report for Adaptive Biotechnologies (NASDAQ:ADPT) was released ...
02-06 05:08
Earnings Scheduled For February 5, 2026
Companies Reporting Before The Bell • WEC Energy Group (NYSE:WEC) is estimated ...
02-05 19:11
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst
Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.
2025-12-16 01:31
Vivakor Announces Special Dividend
Vivakor announced a special dividend of Adapti shares, reflecting its investment in the tech firm and strategic partnerships.
2025-05-30 12:30
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
Adaptive Biotechnologies’ clonoSEQ test for MRD assessment will feature in 30 presentations at ASCO and EHA, including 14 oral presentations, highlighting its clinical impact across multiple blood cancers. The data demonstrate MRD’s transformative role in guiding therapy and improving outcomes in diseases like multiple myeloma and chronic lymphocytic leukemia.
2025-05-30 11:30
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Adaptive Biotechnologies will participate in the Goldman Sachs 46th Global Healthcare Conference, with management scheduled for a fireside chat on June 11. The event aims to showcase their immune medicine platform, which translates adaptive immune system genetics into clinical products for disease diagnosis and treatment.
2025-05-28 20:05
